219672
CFTR Inhibitor III, OXO-172
The CFTR Inhibitor III, OXO-172 controls the biological activity of CFTR. This small molecule/inhibitor is primarily used for Biochemicals applications.
登录查看公司和协议定价
所有图片(1)
别名:
CFTR Inhibitor III, OXO-172, 3-((3-Trifluoromethyl)phenyl)-5-((4-carboxyphenyl)methylene)-4-thiazolidinone, OXO-172
经验公式（希尔记法）:
C18H10F3NO4S
分子量:
393.34
UNSPSC代码:
12352200
推荐产品
质量水平
检测方案
≥95% (HPLC, NMR)
形式
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
off-white
溶解性
ethanol: 1 mg/mL
DMSO: 50 mg/mL
运输
ambient
储存温度
2-8°C
一般描述
A cell-permeable CFTRinh-172 (Cat. No. 219670) 2-oxo analog that exhibits ~25-fold higher aqueous solubility than the 2-thioxo CFTRinh-172 (420 µM vs. 17 µM, respectively, in PBS with 2% DMSO at 25 °C) and great potency, albeit slightly weaker than that of CFTRinh-172, in inhibiting CFTR-mediated apical membrane chloride current upon 20 µM Forskolin (Cat. No. 344270) stimulation in CFTR-expressing FRT cells (IC50 = 1.4 µM vs. 0.38 µM with CFTRinh-172) with practically no cytotoxicity (91% of no-drug control FRT in viability assay; 48 h at 50 µM).
A cell-permeable CFTRinh-172 (Cat. No. 219670) 2-oxo analog that exhibits ~25-fold higher aqueous solubility than the 2-thioxo CFTRinh-172 (420 µM vs. 17 µM, respectively, in PBS with 2% DMSO at 25 °C) and great potency, albeit slightly weaker than that of CFTRinh-172, in inhibiting CFTR-mediated apical membrane chloride current upon 20 µM Forskolin (Cat. No. 344270) stimulation in CFTR-expressing FRT cells (IC50 = 1.4 µM vs. 0.38 µM with CFTRinh-172) with practically no cytotoxicity (91% of no-drug control FRT in viability assay; 48 h at 50 µM).
包装
Packaged under inert gas
警告
Toxicity: Irritant (B)
重悬
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
Sonawane, N.D., and Verkman, A.S. 2008. Bioorg. Med. Chem.16, 8187.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Nathaniel J Henning et al.
Nature chemical biology, 18(4), 412-421 (2022-02-26)
Many diseases are driven by proteins that are aberrantly ubiquitinated and degraded. These diseases would be therapeutically benefited by targeted protein stabilization (TPS). Here we present deubiquitinase-targeting chimeras (DUBTACs), heterobifunctional small molecules consisting of a deubiquitinase recruiter linked to a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门